IFW

OBLON
SPIVAK
MCCLELLAND

MAIER

NEUSTADT

P.C.

ATTORNEYS AT LAW
NORMAN F. OBLON

(703) 413-3000 NOBLON@OBLON.COM

> ROLAND E. MARTIN (703) 412-6243

RMARTIN@OBLON.COM \*BAR OTHER THAN VIRGINIA



DOCKET NO.: 220738US0PCT

## COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 10/088,092

Applicants: Jun ISHIZAKI et al Filing Date: March 21, 2002

For: A GENE ENCODING NOVEL HUMAN SECRETORY

TYPE PHOSPHOLIPASE A2

Group Art Unit: 1652

Examiner: Tekchand SAIDHA

SIR:

Attached hereto for filing are the following papers:

## PTO COVER LETTER RESTRICTION RESPONSE

Our check in the amount of -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Roland E. Martin

Registration No.: 48,082

Customer Number

(703) 413-3000 (phone) (703) 413-2220 (fax)

1940 DUKE STREET ALEXANDRIA, VIRGINIA 22314 U.S.A.
TELEPHONE: 703-413-3000 FACSIMILE: 703-413-2220 WWW.OBLON.COM

DOCKET NO.: 220738US0PCT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

JUN ISHIZAKI, ET AL. : GROUP ART UNIT: 1652

SERIAL NO.: 10/088,092 : EXAMINER: Tekchand SAIDHA

FILED: March 21, 2002

FOR: A GENE ENCODING NOVEL HUMAN SECRETORY

**TYPE PHOSPHOLIPASE A2** 

## **RESTRICTION RESPONSE**

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

This is responsive to the Restriction Requirement mailed June 3, 2004.

Applicants elect, with traverse, the claims of Group I, Claims 1-3, for examination.

Remarks/Arguments begin on page 2 of this paper.